A Relative Bioavailability Study of Moexipril HCl 15 mg Tablets Under Fasting Conditions

Paddock Laboratories, Inc.60 enrolled

Overview

The purpose of this study is to compare the relative bioavailability of Moexipril HCl 15mg tablets (by Paddock Laboratories, Inc.) with that of Univasc® 15mg tablets (by Schwarz Pharma) following a single oral dose (1 x 15mg tablet) in healthy, adult subjects under fasting conditions.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Healthy

Interventions

Moexipril HCl 15mg Tablets, Paddock Laboratories, Inc.DRUG

Univasc® 15mg TabletsDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 45 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Good health as determined by lack of clinically significant abnormalities in health assessment performed at screening Exclusion Criteria: * Positive test results for HIV or Hepatitis B or C * History of allergy or sensitivity to Moexipril HCl or related drugs

Locations (1)

Novum Pharmaceutical Research Services

Pittsburgh, Pennsylvania, United States

Outcomes

Primary Outcomes

Bioequivalence according to US FDA guidelines

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.